S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7). (23rd June 2022)

• Record Type: Journal Article
• Authors: Sureda, A.; Westin, J.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M.; Perales, M.-A.; Farooq, U.; Wannesson, L.; Leslie, L.; Kersten, M. J.; Jacobson, C. A.; Pagel, J. M.; Wulf, G.; Johnston, P.; Rapoport, A. P.; Gordon, L. I.; Yang, Y.; Peng, A.; Du, L.; Snider, J. T.; Shah, J.; Schupp, M.; Cheng, P.; To, C.; Oluwole, O. O.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 112
• Page End: 113
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843736.56298.a7
• Languages: English
• ISSNs: 2572-9241